Articles On Pharmaust (ASX:PAA)

The results of promising preliminary experiments by PharmAust Limited (ASX:PAA), indicating the suppression of a significant proportion of COVID-19 particle cell cultures resulted in the company’s shares trading 50% higher as the market ope...

Perth-based company PharmAust (ASX: PAA) has announced positive preliminary results in experiments aimed at inhibiting the virus that causes COVID-19. Traditionally focused on repurposing existing drugs for cancer therapy, PharmAust is ex...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Today, PharmAust Ltd [ASX:PAA] is the latest in a long list to add to the field of cancer treatment. Delivering a trial outcome that has helped lift the PAA share price as well hopes for a bigger breakthrough to come... The post PharmAust s...

Oncology company PharmAust (ASX: PAA) came out of a trading halt this morning with news that its monepantel canine trial achieved a “successful outcome” with phase 3 trials already on the horizon. The trial is currently on hold pending an i...

PharmAust (ASX:PAA) shares surged this morning on news a clinical trial of its drug that fights cancer in dogs has so far been a success. The company released interim results showing the majority of dogs have responded well to the treatment...

PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, has released promising data in relation to its monepantel canine trial. Management provided an interim trial update for its veterinary Phase II clinical trial investigating the ant...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Clinical stage oncology company PharmAust (ASX:PAA) has entered into a Materials Transfer Agreement with the Walter and Eliza Hall Institute of Medical Research to test the effects of monepantel on COVID-19 infections.

PharmAust Ltd’s (ASX:PAA) wholly owned subsidiary Epichem has produced its first batch of chemistry grade hand sanitiser, and the group’s chemists are also producing hand sanitiser to support and protect members of the community from COVID-...

Today three more ASX small caps entered the fight against COVID-19 and all of them are notching share price gains. The candidates PharmAust (ASX:PAA), Harris Technology (ASX:HT8) and Genetic Technologies (ASX:GTG) all rose by at least 30 pe...

PharmAust Limited (ASX:PAA) has entered into a Materials Transfer Agreement with the Walter and Eliza Hall Institute of Medical Research (WEHI) to test the effects of monepantel (MPL) on COVID-19 infections. Monepantel is PharmAust’s lead d...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Zelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a self-serving myth perpetuated by overzealous users of the intoxicating herb: no one has ever been recorded as overdosing on cannabis over mi...

Special Report: Cannabis products for pets is big business but just two ASX-listed companies are paying it much attention – and only one is making money in the sector. For some pet owners their beloved kitty or canine is their baby, and th...

PharmAust (PAA) claims its business progressed “very successfully” in the 2019 December quarter Its phase 2 trials using monepantel to treat dogs with cancer saw positive progress The company is extending the study with a new dosage and h...

PharmAust (PAA) has received a research and development tax refund of more than $700,000 from the ATO This refund comes after the ATO recognised the innovation of the research and development being undertaken by PharmAust’s subsidiaries...

The European Commission has granted Orphan drug status for Alterity Therapeutics’ (ASX:ATH) lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA). That gives Alterity 10 years of market exclusivity in the European Union...

PharmAust’s (PAA) subsidiary, Epichem, has been awarded an extension to its long-term contract with Drugs for Neglected Diseases initiative, or DNDi DNDi is a non-profit organisation developing new treatments for neglected diseases in vul...

Genetic Technologies (ASX:GTG) shares doubled this morning after the company confirmed the US launch date for its latest breast cancer test. The company says the GeneType product will be released in the US commercially by the end of March....

PharmAust Limited’s (ASX:PAA) wholly-owned subsidiary, Epichem Pty Ltd, has been awarded an extension to its current contract with Drugs for Neglected Diseases initiative (DNDi) (www.dndi.org). PharmAust is a clinical-stage oncology company...

PharmAust Ltd (ASX:PAA), a clinical-stage oncology company developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymp...

Who needs human companionship when we have pets? They’re loyal, always happy to see you and won’t divorce you and take half your stuff. According to the RSPCA, Australia is home to 24 million domestic animals. Dogs were present in 38 per ce...

It can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve small cap. But there are as many moments when CEOs, managing directors, and executive chairmen and women earn their keep. We uncovered the top 1...

Clinical stage oncology company, PharmAust Ltd (ASX:PAA) has provided recruitment guidance for its anti-cancer trialling goals with treatment naïve B cell lymphoma. Previously, PharmAust demonstrated that six of seven dogs with treatment-n...

Clinical-stage oncology company, PharmAust (ASX:PAA) has released its quarterly, highlighting the company's recent successes. PharmAust, which recently completed a capital raise to the tune of $2.4 million primarily to Australian and Singap...

Clinical-stage oncology company, PharmaAust Ltd (ASX: PAA) has announced the appointment of Mr. Colin La Galia as new Chief Executive for its wholly-owned subsidiary – Epichem. Who is Mr. Colin? Colin is a highly experienced executive in...

PharmAust (ASX: PAA), a clinical-stage oncology company, says it has received commitments to raise approximately $2.4 million through a placement.

On Stockhead today: are semiconductors about to pick up again, California’s first pot cafe opens, biotech losers’ remarkable comeback, and angel investment firm Investible closes with $22m round. But first:   The day ahead Today the Austral...

On Stockhead today: Tim Treadgold on why gold miner Pantoro is a stock to watch, milk stocks in healthier shape thanks to Bellamy’s, Barry FitzGerald talks Salt Lake Pot Ash in Explorer’s Podcast and just how much do neobanks scare the Big...

The notion of ‘everything old is new again’ applies not just to fickle fashion trends, but to drug development as well. Drug reformulations are all the rage and it’s not such a bad thing. Think of Paradigm Biopharmaceuticals (ASX:PAR) with...

Oncology company PharmAust (ASX: PAA) is on the home straight to commencing a milestone drug trial following the finalisation of contractual arrangements for its Phase 2 canine cancer trial, to be completed at the University of Melbourne’s...

PharmAust (ASX:PAA), a clinical-stage oncology company, has announced the arrival of its GMP grade monepantel tablets with veterinarians and that it will now commence the phase 2 anti-cancer trial in dogs.

Today Rat's Rant joinsFinfeed as a regular contributor, to provide his irreverent analysis on what Australian stocks are hot and those that not. Today, The Rat looks at why Big Star Energy (ASX:BNL) could be a big star in the future, whethe...

Since the ASX is flooded with quarterlies, we’ve summarised a list of the five health companies that got the biggest share-price boost in morning trade due to 4C releases: Oncosil Medical (ASX: OSL) As Oncosil is at the research and develop...

In this week’s recap of substantial holders, Australian Super became an substantial holder in Gage Roads Brewing (ASX: GRB), a prominent Sydney property magnate bought 16 per cent of Collaborate Corporation, and we look at a number of purch...

Perth-based PharmAust (ASX:PAA) has received ethics approval from the NSW Department of Primary Industry’s Secretary's Animal Care and Ethics Committee to recommence phase 2 clinical trials in pet owners’ dogs with cancer using its...

The below-mentioned healthcare stocks have provided significant returns in the last six months and have come up with major updates today (i.e. 15th July 2019).  Let’s take a look at these updates. Rhinomed Limited (ASX: RNO) A Melbourne-ba...

PharmAust (ASX:PAA), a clinical-stage oncology company, has announced its Perth-based synthetic and medicinal chemistry subsidiary Epichem has paid off its debt liability for a major laboratory expansion undertaken in 2015.